Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Oroxylin A inhibits the generation of Tregs in non-small cell lung cancer.

Shen L, Zhang LL, Li H, Liu X, Yu XX, Hu P, Hui H, Guo QL, Zhang S.

Oncotarget. 2017 Jul 25;8(30):49395-49408. doi: 10.18632/oncotarget.17218.

2.

The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy.

BitMansour A, Pop LM, Vitetta ES.

PLoS One. 2016 Dec 13;11(12):e0167618. doi: 10.1371/journal.pone.0167618. eCollection 2016.

3.

The emerging role of immune checkpoint inhibition in malignant lymphoma.

Hude I, Sasse S, Engert A, Bröckelmann PJ.

Haematologica. 2017 Jan;102(1):30-42. doi: 10.3324/haematol.2016.150656. Epub 2016 Nov 24. Review.

4.

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.

Chaudhary B, Elkord E.

Vaccines (Basel). 2016 Aug 6;4(3). pii: E28. doi: 10.3390/vaccines4030028. Review.

5.

Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node.

Nedelkovska H, Rosenberg AF, Hilchey SP, Hyrien O, Burack WR, Quataert SA, Baker CM, Azadniv M, Welle SL, Ansell SM, Kim M, Bernstein SH.

PLoS One. 2016 May 26;11(5):e0155347. doi: 10.1371/journal.pone.0155347. eCollection 2016.

6.

Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K.

Haematologica. 2016 May;101(5):531-40. doi: 10.3324/haematol.2015.139493. Review.

7.

Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential.

Kocijancic D, Felgner S, Frahm M, Komoll RM, Iljazovic A, Pawar V, Rohde M, Heise U, Zimmermann K, Gunzer F, Hammer J, Crull K, Leschner S, Weiss S.

Oncotarget. 2016 Apr 19;7(16):22605-22. doi: 10.18632/oncotarget.8027.

8.

Pathological conditions re-shape physiological Tregs into pathological Tregs.

Yang WY, Shao Y, Lopez-Pastrana J, Mai J, Wang H, Yang XF.

Burns Trauma. 2015 Dec;3(1). pii: 1. Epub 2015 May 28.

9.

Cancer immunotherapy: Strategies for personalization and combinatorial approaches.

Sathyanarayanan V, Neelapu SS.

Mol Oncol. 2015 Dec;9(10):2043-53. doi: 10.1016/j.molonc.2015.10.009. Epub 2015 Oct 23. Review.

10.

Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions.

Germain C, Guillaudeux T, Galsgaard ED, Hervouet C, Tekaya N, Gallouet AS, Fassy J, Bihl F, Poupon G, Lazzari A, Spee P, Anjuère F, Pangault C, Tarte K, Tas P, Xerri L, Braud VM.

Oncoimmunology. 2015 Apr 8;4(8):e1026503. eCollection 2015 Aug.

11.

Lymphoma Immunotherapy: Current Status.

Zappasodi R, de Braud F, Di Nicola M.

Front Immunol. 2015 Sep 1;6:448. doi: 10.3389/fimmu.2015.00448. eCollection 2015. Review.

12.

PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.

Quan L, Chen X, Liu A, Zhang Y, Guo X, Yan S, Liu Y.

PLoS One. 2015 Sep 11;10(9):e0136476. doi: 10.1371/journal.pone.0136476. eCollection 2015.

13.

The Profile of T Helper Subsets in Bone Marrow Microenvironment Is Distinct for Different Stages of Acute Myeloid Leukemia Patients and Chemotherapy Partly Ameliorates These Variations.

Tian T, Yu S, Liu L, Xue F, Yuan C, Wang M, Ji C, Ma D.

PLoS One. 2015 Jul 2;10(7):e0131761. doi: 10.1371/journal.pone.0131761. eCollection 2015.

14.

Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma.

Lou H, Fang J, Li P, Zhou W, Wang Y, Fan E, Li Y, Wang H, Liu Z, Xiao L, Wang C, Zhang L.

PLoS One. 2015 May 28;10(5):e0126463. doi: 10.1371/journal.pone.0126463. eCollection 2015.

15.

Lymphoma: immune evasion strategies.

Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, Brody JD.

Cancers (Basel). 2015 Apr 30;7(2):736-62. doi: 10.3390/cancers7020736. Review.

16.

Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.

Wang JC, Sindhu H, Chen C, Kundra A, Kafeel MI, Wong C, Lichter S.

PLoS One. 2015 Mar 20;10(3):e0116723. doi: 10.1371/journal.pone.0116723. eCollection 2015.

17.

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival.

Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Novak AJ, Ansell SM.

Blood Cancer J. 2015 Feb 20;5:e281. doi: 10.1038/bcj.2015.1.

18.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P.

N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.

19.

Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP.

Coutinho R, Clear AJ, Mazzola E, Owen A, Greaves P, Wilson A, Matthews J, Lee A, Alvarez R, da Silva MG, Cabeçadas J, Neuberg D, Calaminici M, Gribben JG.

Haematologica. 2015 Mar;100(3):363-9. doi: 10.3324/haematol.2014.110189. Epub 2014 Nov 25.

20.

Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations.

Song JY, Pittaluga S, Dunleavy K, Grant N, White T, Jiang L, Davies-Hill T, Raffeld M, Wilson WH, Jaffe ES.

Am J Surg Pathol. 2015 Feb;39(2):141-56. doi: 10.1097/PAS.0000000000000328.

Supplemental Content

Support Center